Investor Relations

Martin Mackay, Ph.D., is the Independent Chair of Charles River’s Board of Directors. Dr. Mackay is co-founder, former Chief Executive Officer, and current Non-Executive Chairman of Rallybio, a privately-held early-stage biotechnology company incorporated in January 2018. Previously, he was Executive Vice President, Head of Research and Development at Alexion from 2013 until 2017. Prior to joining Alexion, Dr. Mackay served as President, Research and Development at AstraZeneca from 2010 to 2013, where he led the research and development (R&D) functions worldwide, including discovery research, clinical development, regulatory affairs, and key related R&D functions. From 1995 to 2009, he held various positions at Pfizer Inc., including Senior Vice President of Worldwide Development, where he was a member of the Executive Leadership Team and led a global organization tasked with advancing a portfolio of investigational medicines across a range of disease areas, and President, Head of Pfizer Pharmatherapeutics, R&D, where he oversaw all aspects of small molecule discovery and development across multiple therapeutic areas. From 1986 to 1995, Dr. Mackay worked at Ciba-Geigy (now Novartis) in the United Kingdom and Switzerland, and held various positions in academic research prior to that time. Dr. Mackay previously served as a director of Novo Nordisk and SpringWorks Therapeutics. Dr. Mackay has been a director since July 2017.